Bladder cancer biological samples:
Research application and procurement

The development of drugs and diagnostic tests for the treatment and detection of bladder cancer requires conducting studies on biological samples obtained from patients with bladder cancer.

A brief overview of the various bladder cancer types and how the services offered by Labtoo contribute to accelerating research and development projects in the pharmaceutical industry.


Are you looking for biological samples from bladder cancer patients?

What are bladder tumors?

Cancerous bladder tumors are often classified based on their stage of advancement, indicating the extent of tumor invasion into layers beyond the original. The distinctions are as follows:

Non-invasive tumors

Also referred to as superficial tumors or NMIBC (Non-Muscle-Invasive Bladder Cancer), these tumors remain at the urothelium cell level and do not extend into the muscular cells of the bladder.

Invasive tumors

Or MIBC (Muscle-Invasive Bladder Cancer), representing more severe cases. In this context, tumors have infiltrated the muscular cells, significantly increasing the likelihood of metastasis.

Type of Bladder Cancer Origin Cells Frequency
Urothelial Carcinoma (or Transitional) Urothelial Cells ≈ 90%
Squamous Cell Carcinoma Squamous Cells 3 - 8%
Adenocarcinoma Glandular Cells 1 - 2%
Neuroendocrine Carcinoma Neuroendocrine Cells > 1%
Sarcoma Mesenchymal Cells > 1%


Labeled anatomical diagram of a Bladder

The vast majority of bladder cancers (90%) are urothelial carcinomas, or transitional cell carcinomas. These tumors originate from cells lining the interior of the bladder (the uterine mucosa).

In rare cases of invasive tumors extending beyond the inner lining, the cancer may consist of various cell types intermingled with urothelial cancer cells. This phenomenon is termed divergent differentiation, and the most commonly found cells are squamous cells (squamous cell carcinomas) and glandular cells (adenocarcinoma).

Bladder cancer can be metastatic, categorized as Stage IV. Most commonly, metastases from the bladder migrate to lymph nodes, liver, lungs, and bones.

favicon large un peu plus-1 1

Explore Labtoo's Service for Your Biological Sample Research

Labtoo assists you in sourcing biological samples from bladder cancer patients. Our team manages the entire project of transferring biological materials from inception to sample delivery.

  • Feasibility assessment of sample availability or clinical collection from referenced clinical centers
  • Validation of regulatory aspects
  • Establishment of a contractual framework
  • Dispatch of desired samples under appropriate conditions
  • Transfer of associated clinical data
  • Additional analytical and experimental services

Types of available samples


Fresh tissues

After a tumor resection or a biopsy, a pathologist can decide whether the tissue sample can be used for research. Labtoo can organize the conditioning and shipment of fresh bladder cancer tissue in 24-48 hours after surgery.

Frozen tissues (OCT and FF)

Similarly to fresh tissue, once the tissues are cleared for research, the clinical site can freeze and keep the frozen bladder tissue samples at -80°C or in liquid nitrogen for ulterior use.


FFPE Tissues

Pathologists typically embed the biopsies and resections in paraffin. FFPE blocks of bladder cancer tissues can be used later for research.



Adjacent Healthy Tissues

Tumor resections typically include healthy adjacent bladder tissue during the process. This tissue can later be used for research and act as controls for diseased tissues.


Blood derivatives
  • Plasma or Serum from bladder cancer patients
  • PBMC (Peripheral Blood Mononuclear Cells)
  • Whole Blood
  • Leukapheresis
  • Urine
  • Feces
  • Other

Typical associated clinical data

    • Age
    • Gender
    • Ethnicity
    • TNM Classification
    • Undergone Treatment
    • Medical Imaging
    • Positivity/Negativity for certain Infections
    • Mutations
    • Other Data (upon request)
Samples blood Labtoo 200-1

Our service identifies clinical sites capable of preparing and transferring a sample collection for a specific project.

Contact our team to discuss your project.

The stages and grades of bladder cancer

The stage and grade of cancer are commonly used together to provide a comprehensive assessment of the disease and guide optimal treatment.

The determination of cancer stage primarily relies on the TNM classification, which evaluates the tumor size (T), involvement of lymph nodes by cancer cells (N), and the presence of metastases in other parts of the body (M). Concurrently, the grade provides an indication of the degree of differentiation of cancer cells.

Regarding grades, denoted from 1 to 3, Grade G1 indicates well-differentiated cells resembling normal cells, Grade G2 represents moderately differentiated cells, and Grade G3 indicates poorly differentiated cells, suggesting faster and potentially more aggressive growth.

For bladder cancer, the stages are defined as follows:

Stage 0

The tumor is confined to the lining of the bladder, termed "carcinoma in situ."




Stage I

The tumor has invaded the connective tissue layer of the bladder.




Stage II

The tumor has penetrated the muscular layer of the bladder, becoming invasive.




Stage III A

The tumor has invaded tissues adjacent to the bladder outside, without reaching the pelvic or abdominal wall. Alternatively, the cancer has spread to a lymph node in the pelvic region.

Stage III B

The cancer spread to at least 2 lymph nodes in the pelvic region or at least 1 lymph node above the pelvic region.


Stage IV A

Invasion of cancer into the pelvic or abdominal wall or invasion of the farthest lymph nodes from the bladder.

Stage IV B

Presence of metastases in other parts of the body, such as the liver, bones, or lungs.


Rare forms of bladder cancer


Occasionally, rarer forms of bladder cancer may develop, among which are:

  • Squamous Cell Carcinoma

    This type of cancer originates from flat cells of the epithelium.

  • Adenocarcinoma

    A cancer that forms from glandular cells of the bladder.

  • Small Cell Carcinoma

    A cancer taking shape in the neuroendocrine cells of the bladder.

  • Sarcoma 

    Cancer that develops in soft tissue cells. In the case of the bladder, leiomyosarcomas are most commonly found in adults, while rhabdomyosarcomas are more prevalent in children.

Bladder cancer treatments and advances

The primary treatment for bladder cancer typically involves surgical intervention, with tumor removal in cases of non-invasion or, in more advanced cases, bladder resection along with adjacent structures, such as the prostate in men or the uterus and urethra in women. Additional procedures, including chemotherapy, immunotherapy, or radiotherapy, may be considered depending on the severity of the disease.

Recent advancements in bladder cancer treatment have focused on targeted therapies, an approach that directly targets specific molecules present in tumors. Among these breakthroughs, antibody-drug conjugates stand out. These medications merge a monoclonal antibody with a chemotherapeutic substance.

The antibodies are designed to selectively bind to proteins on the surface of cancer cells, facilitating the internalization of the cytotoxic substance and the targeted destruction of cancer cells.

Samples blood Labtoo 200-1

You could not find what you are looking for? Search for your service here: 

    Supplementary resources

    Sample EN
    Drug dev EN-1
    RNA EN-min